news paper icon

Analyzed News

Novartis gains U.S. approval for delayed MS drug

ZURICH (Reuters) - Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market. [Source]

Publication Date:


Category: healthNews

Topics: approval, drug, glatopa, larger, division

Source Link:

Related Articles